Humabs isolates antibody targeting all influenza A viruses
This article was originally published in Scrip
Humabs BioMed, a Swiss biotech that includes Chiron founder and seasoned veteran Bill Rutter as a backer, has secured exclusive worldwide rights to a technology that could yield a universal flu treatment. The approach is based on a neutralising antibody selected from plasma cells that binds to all 16 subtypes of group 1 and group 2 influenza A haemagglutinins. Details of the isolated antibody, dubbed F16 and achieved by researchers working in British and Swiss laboratories, have been published on-line in Science.